Dr Timothy Yap speaks to ecancer about the PETRA trial that he presented at the AACR 2022 meeting. The trial was a first in class, first in human trial of the next generation PARP1-selective inhibitor AZD5305 in patients with BRCA1/2, PALB2 or RAD51C/D mutations.

He reports that the results showed that AZD5305 successfully improved safety and showed promising clinical activity.

Dr Yap believes that this is proof of concept in the clinic for this innovative strategy and that expansion trials are in the works.